Dystrogen Therapeutics
Business Services · Illinois, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1415 W 37th St, Chicago, Illinois, 60609...Phone Number
(779) 248-2313Website
www.dystrogen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Dystrogen Therapeutics
Dystrogen Therapeutics is a clinical-stage biotech company specializing in chimeric cell therapy aimed at treating muscle wasting disorders, particularly Duchenne muscular dystrophy (DMD). The company is developing Dystrophic Expressing Chimeric (DEC) cell therapy, which offers a universal treatment option without the need for immunosuppression. Their innovative approach allows for the production of the dystrophin protein without genetic manipulation, making it suitable for all DMD patients regardless of their genetic mutations. Dystrogen Therapeutics targets patients suffering from DMD, providing a novel solution that enhances muscle function and reduces fatigue.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dystrogen Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Dystrogen Therapeutics
Check out if Dystrogen Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Dystrogen Therapeutics has new funding data
Earning: See what the market has to say on Dystrogen Therapeutics recently announced quarterly report
Dystrogen Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Dystrogen Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Dystrogen Therapeutics launches new products
Check if Dystrogen Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Dystrogen Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Dystrogen Therapeutics
Compare insights from companies similar to Dystrogen Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Dystrogen Therapeutics
<$5M
1-10
Private
-
2017
N/A
<$5M
11-50
Private
<$5M
2005
CL
Cynthia LevinthalPrincipal Consultant. Neural Stem Cell Therapies. Clinical Trials
Company Profile Activity
Activity Insights
Dystrogen Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dystrogen Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dystrogen Therapeutics.
Dystrogen Therapeutics Tech Stack
A closer look at the technologies used by Dystrogen Therapeutics
See more technologies
Dystrogen Therapeutics News & Media
Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for the Treatment of Duchene Muscular Dystrophy Shows Safety and Functional Improvements
Results continue to reinforce safety and tolerability profile of DT-DEC01 First look at functional outcomes in low dose cohort found improvements 3 months after DT-DEC01 administration Therapy not dependent on the genetic mutation of the DMD patient, thus making DT-DEC01 a universal...Dystrogen Therapeutics Announces First in Man Dosing of Novel Chimeric Cell Therapy for Duchenne Muscular Dystrophy and Reports 6-week Clinical Outcomes
MIAMI, Jan. 4, 2022 /PRNewswire/ -- Dystrogen Therapeutics Corp. a clinical-stage company developing chimeric cell therapeutics to modify the course of rare diseases, today announced dosing of the first patient in its Phase 1 Human Pilot Clinical Study of DT-DEC01, Dystrophin Expressing...Dystrogen Therapeutics Announces That Treatment With Dystrophin Expressing Chimeric (DEC) Cells Improves Cardiac Function in Preclinical Duchenne's Study
CHICAGO, Nov. 5, 2019 /PRNewswire/ -- Scientists from Dystrogen Therapeutics Corp. published data supporting cardioprotective effects of the Company's therapy for muscular dystrophy disorders. Cardiomyopathy is the most devastating cause of morbidity and mortality in Duchenne Muscular...Dystrogen Therapeutics Announces That Gene Therapy Successfully Cuts Off Production of Neuron-Destroying Protein in Huntington's Disease
CHICAGO, April 5, 2019 /PRNewswire/ -- Scientist from Dystrogen Therapeutics Corp. will present data supporting a potential cutting-edge therapy for neurodegenerative diseases caused by trinucleotide repeats, such as Huntington's disease (HD) and spinocerebellar ataxias (SCAs). Early data ...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Dystrogen Therapeutics
Sign Up For FreeTo access detailed company insights
Dystrogen Therapeutics is a clinical-stage biotech company specializing in chimeric cell therapy aimed at treating muscle wasting disorders, particularly Duchenne muscular dystrophy (DMD). The company is developing Dystrophic Expressing Chimeric (DEC) cell therapy, which offers a universal treatment option without the need for immunosuppression. Th... Read More
